Diagnosis of Hepatocellular Carcinoma by Kefeli, Ayse et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Diagnosis of Hepatocellular Carcinoma
Ayse Kefeli, Sebahat Basyigit and
Abdullah Ozgur Yeniova
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64992
Provisional chapter
Diagnosis of Hepatocellular Carcinoma
Ayse Kefeli, Sebahat Basyigit and
Abdullah Ozgur Yeniova
Additional information is available at the end of the chapter
Abstract
Hepatocellular  carcinoma  (HCC)  is  one  of  the  commonest  cancers  worldwide,
particularly in the developing countries HCC occurs predominantly in patients with
underlying chronic liver disease and cirrhosis, especially due to chronic hepatitis C virus
(HCV) and hepatitis B virus (HBV) infection. Tumors progress with local expansion,
intrahepatic spread, and distant metastases, and the life expectancy of patients with
HCC is poor, with a mean survival of 6–20 months. Thus, developing effective and
efficient care for patients with HCC must become a significant subject. Removal of HCC
by surgical, transplantation or resection of the tumors, means offers the best chance for
possible cure. Criteria for such intervention have been refined over the last decade to
optimize long-term survival in selected patients with Milan criteria. Not many patients
are candidate given the advanced stage of their cancer at diagnosis or degree of liver
disease. The other main limiting factor is inadequate organ storage. Unfortunately,
many patients die when they are waiting a donor organ. Local ablative therapies may
be effective for time saving as a bridge therapy, and may provide palliation, in these
patients. Diagnostic tools commonly used include radiographic imaging, and rarely
serum markers  and liver  biopsy.  A suspicious  lesion  on  the  ultrasound generally
requires additional imaging studies to confirm the diagnosis of the tumor. Histologic
confirmation is not required in a patient at increased risk for hepatocellular carcinoma
whose lesion(s) fulfill criteria for hepatocellular carcinoma which are presence of typical
features,  including  hypervascularity  during  arterial  phase  followed  by  decreased
enhancement (washout) during portal venous phases on computerized tomography or
has increased T2 signal intensity on magnetic resonance imaging.
Keywords: hepatocellular carcinoma, alpha fetoprotein, computerized tomography,
magnetic resonance imaging
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1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver that usually
develops in the setting of chronic liver disease. It is the fifth most common cancer in men
and the eighth most common in women and is the second leading cause of cancer-related
death in the world [1]. Moreover, incidence of HCC is increasing despite limited number of
cancer registries, underdiagnosis of HCC, particularly in developing countries. Therefore, the
ability to make a diagnosis of HCC at an early time has a critical role to providing effective
treatment,  including  curative  treatment  such  as  surgical  resection,  liver  transplantation.
Hereby, surveillance program has been developed to provide early treatment and updated
guidelines recommend that groups were specified for which surveillance who has chronic
liver disease, was likely to be cost-effective because the HCC incidence was high enough [2–
6]. Eventually, surveillance programs with the purpose of early detection of HCC, primarily
through serum markers as alpha-fetoprotein (AFP) assessment and hepatic imaging, have
led to archive to early diagnosis and curative treatment in patients with HCC [7]. When
hepatic lesion is identified by surveillance program, the diagnosis of HCC can be made by
the use of dynamic imaging series, tumor markers, and rarely liver biopsy. Imaging modal-
ities have primary role to establishing the diagnosis of HCC but serum tumor markers and
liver biopsy continue to have important role, particularly in the setting of small or atypical
hepatic lesion. On the other hand, unfortunately, no universal guidelines for diagnosis exist,
which may be because of the differences in the diagnostic approach between Eastern and
Western institutions. The aim of this chapter is to provide an extensive review of the current
modalities  employed  for  the  diagnosis  of  HCC,  including  serum  markers,  radiological
techniques  and  histological  evaluation,  and  comparison  international  guidelines  for  the
diagnostic approach to HCC.
2. Diagnosis of Hepatocellular Carcinoma
The diagnostic approach to the solid liver lesion is commonly determined by the size of the
lesion. The diagnostic approach differs according to whether lesion is lesser or larger than
1 cm. The American Association for the Study of Liver Diseases (ASLD) and Korean Liver
Cancer study Group-National Cancer Centre Korea (KLCSG-NCC) guidelines recommend
follow-up ultrasound (US) every three-six months if the lesions are lesser than 1 cm and require
definitive contrast-enhanced imaging with either 4-phase computed tomography (CT) or
magnetic resonance imaging (MRI) (Figure 1) if the lesions are larger than 1 cm; otherwise
European Association for the Study of the Liver (EASL) guidelines have different algorithm
which had three ways; first one is which nodules are lesser than 1 cm, second one is in diameter
1–2 cm, and third one is larger than 2 cm. On the other hand, Asian Pacific Association for the
Study of the Liver the Asian Pacific Association for the Study of the Liver (APASL) guideline
ignores the size of the liver lesion. Recent guidelines have some diversity, and thus, all
algorithms of guidelines were presented in figures (Figures 1–4) [2–6].
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Figure 1. Diagnostic algorithm of AASLD guideline for nodule by detected US in patients at risk of HCC.
Figure 2. Diagnostic algorithm of EASL guideline for nodule by detected US in patients at risk of HCC.
Diagnosis of Hepatocellular Carcinoma
http://dx.doi.org/10.5772/64992
97
Figure 3. Diagnostic algorithm of APASL guideline for nodule by detected US in patients at risk of HCC.
Figure 4. Diagnostic algorithm of JAPAN for nodule guideline by detected US in patients at risk of HCC.
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Histologic confirmation is not required in a patient at increased risk of hepatocellular
carcinoma whose lesion(s) fulfill criteria for hepatocellular carcinoma which are the presence
of typical features on 4-phase CT or MRI, including hypervascularity during arterial phase
followed by decreased enhancement (washout) during portal venous phases on CT or has
increased T2 signal intensity on MRI. However, if the diagnosis remains unclear, the lesions
did not have these specific features, and the results will affect the patient's management, and
a biopsy of the lesions is indicated. Biopsy is rarely needed due to valuable contribution of
serum markers on diagnosis of HCC. Although elevated serum AFP levels had been
evaluated in guidelines previously, almost all of recent guidelines no longer include meas-
urement of serum AFP in the diagnostic algorithm for hepatic nodules found on surveillance
program [2, 3].
With the Asian, American, and European guidelines, Liver Imaging Reporting and Data
System (LI-RADS) has been developed to address the limitations of prior imaging-based
criteria including the lack of established consensus regarding the exact definitions of imaging
features, binary categorization (either definite or not definite HCC), and failure to consider
non-HCC malignancies [8].
Comparison of the EASL, AASLD, APASL, and LI-RADS guidelines are summarized in
Table 1.
EASL AASLD APASL JAPAN LI-RADS
Target population Cirrhosis Hep B carriers,
cirrhosis
Cirrhosis only with
Hep B or Hep C
All patients at
high risk of HCC
All patients at high
risk of HCC
Targeted lesion Detected nodule
by US
Detected nodule
by US
Detected nodule by
US and elevated
AFP
Detected nodule
by US and
elevated AFP, AFP-
L3, DCP
All nodules
Imaging modality 4-phase MDCT,
CE-MRI
4-phase MDCT,
CE-MRI
CT, CEUS, SPIO-
MRI
CT, CEUS, Gd-
EOB-DTPA-
enhanced
MRI, CT
angiography
CT, MRI with
extracellular and
hepatobiliary agent
Diagnostic criteria Larger than 1 cm Larger than 1 cm Washout on
PVP, DP or
AP enhancement AP enhancement
AP enhancement AP enhancement High SPIO-MR
signal or
Washout on DP Washout on
PVP, DP
Washout on
PVP, DP
Washout on
PVP, DP
Defect in KP on
CEUS
Larger than1 or
1.5 cm
Capsule appearance
*Regardless of the
size
Number of
requiredexam
≥2 cm: one exam One exam One exam One exam One exam
1–2 cm: two
exams
Serum marker N/A N/A Only for small
nodules (<1 cm)
Yes N/A
Category of
diagnosis
HCC HCC HCC HCC LR-1 definitely
benign
Not HCC Not HCC Not HCC Not HCC LR-2 probably
benign
Indeterminate Indeterminate Indeterminate Indeterminate LR-3 indeterminate
Diagnosis of Hepatocellular Carcinoma
http://dx.doi.org/10.5772/64992
99
EASL AASLD APASL JAPAN LI-RADS
LR-4 probably HCC
LR-5 definitely HCC
LR-5V definitely
tumor invading vein
LR-M probably
malignancy but not
specific for HCC
Diagnosis of
subcentimetre HCC
without biopsy
No No Yes (tumor marker
+ imaging)
No Yes (probably HCC)
Biopsy required Yes Yes No Yes Yes (LR-4, LR-M)
AASLD: Association for the Study of Liver Diseases; AFP: alpha-fetoprotein; AP: arterial phase; CHB: chronic hepatitis
B; CHC: chronic hepatitis C; DP: delayed phase; EASL: European Association for the Study of the Liver; 4-phase
MDCT: +phase multidetector computerized tomography; CE-MRI: contrast-enhanced magnetic resonance imaging;
HCC: hepatocellular carcinoma; KLCSG-NCC: Korean Liver Cancer Study Group-National Cancer Center; LC: liver
cirrhosis; LI-RADS: Liver Imaging Reporting and Data System; N/A: not applicable; PVP: portal venous phase; TP:
transitional phase; US: ultrasonography; KP: Kupfer.
Table 1. Comparison of EASL, AASLD, APASL guidelines, and LI-RADS.
2.1. Serum markers
Ideal biomarkers should provide or contribute to diagnose and to monitor a disease, with a
sufficient sensibility and specificity, to define its stage as well as to allow an easy and repro-
ducible screening in the target population, with a low cost.
Serum AFP concentration is the most commonly used marker for HCC. Although several other
serologic markers [such as des-gamma-carboxyprothrombin (DCP), glypican 3] may signify
the presence of HCC, they are just used in combination with the serum AFP which may
improve the diagnostic accuracy. These markers are not common used in alone in routine
clinical practice.
2.1.1. Alpha-fetoprotein
However, serum levels of AFP do not correlate always with other clinical features of HCC such
as size, stage, or prognosis, and AFP is the most common used marker for HCC. Because of
AFP is normally produced during gestation by the fetal liver and yolk sac, the serum concen-
tration of AFP can be increased during pregnancy with tumors of gonadal origin (both germ
cell and non-germ cell) and in a variety of other malignancies [9]. Elevated serum AFP can also
be seen in patients with chronic liver disease without HCC such as acute or chronic viral
hepatitis, particularly in hepatitis C [10].
However, the accuracy of AFP has been critically challenged, and there is growing debate about
its continued use in HCC surveillance programs, and AFP appears to be beneficial in clinical
practice. In addition, many guidelines including EASL and ASLD no longer recommend
measuring AFP level for surveillance of HCC. Only Asian Guideline recommends US and AFP
every 6 months. However, a rise in serum AFP in a patient with cirrhosis or hepatitis B alerts
the physician on possible HCC development.
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In practice, it is generally accepted that serum levels greater than 500 mcg/L (normal in most
laboratories is between 10 and 20 mcg/L) in a high-risk patient are diagnostic of HCC [11]. On
the other hand, HCC is often diagnosed at a lower AFP level in patients undergoing screening
[9] because all tumors do not secrete AFP, and serum concentrations are normal in up to 40%
of small HCCs [12]. Elevated serum levels of AFP are commonly associated with HCC causing
on advanced-stage fibrosis. Persistently elevated AFP values in a patient with cirrhosis have
an increased risk of developing HCC compared with those who have fluctuating or normal
levels (29% vs 13 and 2.4%, respectively, in one report) [13].
The sensitivity, specificity, and predictive value for the serum AFP in the diagnosis of HCC
is still controversial issue. There is no strict cutoff value. Commonly accepted value is >20
mcg/L and a review which have five studies showed that sensitivity was 41–65% and
specificity was 80–94% based upon a cutoff value of >20 mcg/L [14].
An increase in AFP level may be has a greater diagnostic accuracy than one time measurement
of AFP whether higher than cutoff value. Using longitudinal AFP measurements could have
identified an increase in AFP. Requiring an increase in AFP level of ≥2 from its nadir in the
prior year maintained high sensitivity of surveillance while increasing specificity. This finding
confirms prior studies [15].
Although ASLD and EASL guidelines recommend using US alone to achieve this goal given
concerns about the suboptimal sensitivity and specificity of AFP [2, 3], and when AFP used in
combination with US, its sensitivity reaches up to 63% for early-stage HCC [16].
Despite the poor reliability and low sensitivity of serum AFP for the diagnosis of HCC, it has
emerged as an important prognostic marker, especially in patients undergoing resection and
those being considered for liver transplantation. In addition, an increase in AFP is associated
with increased tumor size and stage, extrahepatic metastasis, portal vein thrombosis, and
decreased survey. Patients with AFP levels >1000 mcg/L have an extremely high risk of
recurrent disease following transplantation, irrespective of the tumor size [17, 18].
2.1.2. AFP-L3
AFP-L3 is molecular variant of AFP, in which different isoforms of AFP, which can be identified
through electrophoretic techniques relied on specific lectins, have long been reported in the
biomedical literature [19]. Because of the limitations of serum AFP measurements, several
other molecular variants of AFP, such as AFP-L3, have been evaluated for diagnosis or
estimating prognosis in patients with HCC. Lens culinaris agglutinin-reactive AFP (AFP-L3)
is a newly developed assay, highly sensitive fraction of AFP (hs-AFP-L3) that has been used
as a diagnostic and prognostic marker of HCC. In patients with AFP < 20 ng/mL, measurements
of AFP-L3% by the highly sensitive method before treatment was more useful for diagnosis
and prognosis of HCC than by the conventional method [20].
Furthermore, since hs-AFP-L3% increases before HCC is detectable by various advanced
imaging modalities, this assay may help identify benign liver disease patients with a higher
risk of HCC [21].
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2.1.3. MicroRNAs
Recently, miRNAs have been widely reported as a new class of clinical biomarkers and
potential therapeutic targets for cancers. Because miRNAs act as key factors in several
biological processes, such as growth, cell proliferation, differentiation, apoptosis, and carci-
nogenesis. HBV- or HCV-related HCC development and progression are associated with a
significant and important deregulation of serum/plasma and liver tissues' profiles of miRNAs,
as it has been widely reported by several studies. Thus, this evidence makes miRNAs potential
and useful biomarkers for diagnosis, staging, progression, prognosis, and response to treat-
ment. Therefore, in the last years, a large series of studies has been performed to investigate
the correlation between specific miRNAs levels and/or profiles in body fluids and HCC [22, 23].
miRNAs have some usefulness characteristics, including the possibility to detect these
molecules in serum/plasma samples, that may be easily collected, and their high stability, even
in conditions that are generally known to induce RNAs degradation, such as fluctuations in
temperature and pH levels as well as long-term storage [24, 25]. Although some studies showed
that miRNA panels can be used to discriminate HCC patients from cancer-free controls, and
could be a blood-based early detection biomarker for HCC screening, and demonstrated as
important regulators in HCC pathogenesis, definitive conclusions about relationship between
the majority of miRNAs and HCC remain to be explored [26–28].
2.1.4. Des-gamma-carboxyprothrombin
DCP, also known as the protein induced by vitamin K absence or antagonist II (PIVKA-II), is
an abnormal form of the coagulation protein, prothrombin. The vitamin K-dependent carbox-
ylase responsible for the carboxylation is absent in many HCC cells, and an abnormal pro-
thrombin with all or some of unconverted glutamic acid is secreted. Therefore, this non-
carboxylated form (DCP) has been used as an HCC biomarker [29, 30].
The sensitivities for AFP, AFP-L3%, and DCP were 68, 62, and 73%, respectively. When the
three markers were combined, the sensitivity was increased to 86%. In another study, DCP
levels were shown to correlate with tumor size and metastatic HCC. Several studies that are
compared to AFP and DCP had the highest sensitivity (67–63% vs 73–87% for DCP), specificity
was the highest in DCP in comparison with AFP (91% vs 78% respectively), and the highest
positive predictive value (87%) in patients with HCC [31, 32]. APASL guideline recommends
simultaneous measurement of AFP and DCP [4]. In addition, elevated serum DCP is signifi-
cantly related to portal vein invasion and/or intrahepatic metastasis. It recommends simulta-
neous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence
for detecting hepatocellular carcinoma [31, 32].
DCP can be elevated in other conditions besides HCC. Conditions such as obstructive jaundice,
intrahepatic cholestasis causing chronic decrease in vitamin K, and ingestion of drugs such as
warfarin or wide-spectrum antibiotics can result in high concentrations of DCP. In addition,
25–50% of patients with HCC will have a DCP value within the reference range. Because of
this, a normal DCP value does not rule out HCC.
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Simultaneous determinations of AFP and DCP are useful for monitoring recurrence in patients
with HCC after treatment, but the decrease to normal levels of a single marker does not always
indicate the absence of tumor recurrence [33].
2.1.5. Glypican-3
Glypican (GPC) is a family of heparan sulfate proteoglycans that are bound to the cell surface
by a lipid anchor. Six members (GPC1∼6) of this family have been identified. New finding of
recent research is that GPC-3 expression is closely associated with hepatocyte malignant
transformation [34] and is a specific oncofetal biomarker for HCC diagnosis [35].
A number of studies showed that a very high specificity (90–100%) associated with serum
GPC-3 in patients with HCC, but the sensitivity of serum GPC-3 remained relatively low;
however, if GPC-3 measured combined with AFP, sensitivity appears to improve [36, 37].
2.1.6. Proteomic profiling
The fields of proteomic-based biomarker discovery have applied advanced tools to identify
early changes in protein and metabolite expression in HCC. Although, with robust validation,
it is anticipated that from these candidates will rise a high-performance noninvasive test able
to diagnose early HCC and related condition, a meta-analysis which is reviewed 22 studies,
showed only six assessed the diagnostic performance of the biomarker candidates proposed
[38]. Therefore, these biomarkers have not been currently recommended for surveillance or
diagnosis.
2.1.7. Other serum markers
Other serum markers of HCC that have been studied include the following:
• Tumor-associated isoenzymes of gamma-glutamyl transpeptidase: Isoenzymes were
present in 42% of hepatocellular carcinoma patients with a normal serum alpha-fetoprotein
concentration and in 50% of those with a non-diagnostic value [39].
• Urinary transforming growth factor beta-1: Transforming Growht Factor (TGF)-beta1
showed a high specificity (99%), but the sensitivity was 53.1%. The determination of both
markers TGF-beta1 and AFP in parallel significantly increased the diagnostic accuracy
(90.1%) and sensitivity (84%), with a high specificity (98%) and positive likelihood ratio [40].
• Serum alpha-L-fucosidase activity [41].
• Human carboxylesterase 1 [42].
• Acetylcarnitine [43].
2.2. Imaging studies
Imaging studies have main role to make a diagnosis of HCC. While Japan, and KLCSG-NCC
guidelines' recommendations are based on serum biomarkers and imaging studies, APASL,
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EASL guideline and ASLD guidelines' recommendations are just based on imaging findings
for diagnosis of HCC. US, CT, MRI, and angiography are the imaging tests which are most
commonly used for the diagnosis of HCC. Basically, a unique dynamic radiological behavior
(contrast uptake in the arterial phase and early washout on portal phase or delayed phase by
CT, MRI, angiography, or contrast-enhanced US) represented the backbone of radiological
diagnosis of early HCC [2–6].
HCC can have a variety of size and appearances on imaging studies; such as small hypo-hyper
vascular nodules or massive mass, which may have necrosis, fat and/or calcification, nodular
multiple masses of variable attenuation which may also have central necrosis, and infiltrative
diffuse lesion [44].
2.2.1. Ultrasound
US is the preferred modality for surveillance of HCC in patients with chronic liver disease, and
if a lesion is found on US, the lesion/lesions is/are evaluated by advance imaging tests [2–6].
While US has many advantages including low-cost, noninvasive, high availability, and high
specificity, it has several disadvantages such as low sensitivity and depending on the operator.
Thus, US should be used as a screening test, not as a diagnostic test for HCC. Otherwise,
contrast-enhanced ultrasound (CEUS) can be used as a diagnostic test because it is as sensitive
as dynamic CT or MRI in the diagnosis of HCC [4].
HCC can be appeared variable imaging structure; mostly small focal HCC appears hypoechoic
compared with normal liver, larger lesions which are heterogeneous due to fibrosis, fatty
change, necrosis, and calcification [45]. A peripheral halo of hypoechogenicity may be seen
with focal fatty sparing, diffuse lesion which may be difficult to identify or distinguish from
background cirrhosis [46].
2.2.2. Computerized tomography
Accurate technical performance of 4-phase CT scanning with imaging in the hepatic arterial
and venous–portal venous, as well as delayed contrast images, is extremely important to
characterize the lesions in detecting HCC because there are sequential changes in the supplying
vessels and hemodynamic state during hepatocarcinogenesis [47]. If early vascular imaging is
not performed, some lesions can be missed. It is important to use high injection rates and
appropriate bolus timing. Sensitivity of good-quality 4-phase CT scanning for the detection of
patients with tumors is 60–94.4%, in tumor larger than 1 cm, and its sensitivity reduced by 33–
45% for detecting tumors smaller than 1 cm [48]. The hallmark of HCC during CT scan is the
presence of arterial enhancement followed by washout meaning becoming indistinct or
hypoattenuating of the tumor in the portal-venous and/or delayed. The presence of arterial
enhancement followed by washout has a sensitivity and specificity of 90 and 95%, respectively
[49–52].
Small, arterially enhancing nodules are common in the cirrhotic liver, and majority of these
nodules are benign [53, 54]. Thus, every attempt, including imaging follow-up or biopsy,
should be made to characterize these nodules [55].
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In patients with HCC, unenhanced CT typically shows an isohypodense mass. If the mass is
large, central areas of necrosis may be seen that are typically hypodense during this imaging
phase.
In the hepatic arterial phase, HCCs typically are hyperdense (relative to hepatic parenchyma)
and arterioportal shunt can occur as they are hypervascular tumors. Therefore, wedge-shaped
perfusion abnormality due to arterioportal shunts can be seen and can result in a focal fatty
change in the normal liver or focal fatty sparing in the diffusely fatty liver [56]. A halo of focal
fatty sparing may also be seen around an HCC in an otherwise fatty liver [57].
The portal venous phase coincides with peak parenchymal enhancement is characterized by
enhancement of hepatic veins as well as portal veins. In this phase, small lesions may be
isodense or hypodense and distinguish from the parenchyma is difficult, as the remainder of
the liver increases in attenuation. Larger lesions with necrotic regions remain hypodense [58].
The portal venous and delayed phases can also evaluate nodule diameter, depicting hypovas-
cular nodules including low- or high-grade dysplastic nodules, early HCCs, and well-
differentiated HCC. Portal blood flow may be maintained in some cases of dysplastic nodules
and early HCC but reduced in other nodules, although the pathology remains because of early
HCC, in which arterial blood flow has not yet increased. In addition, these phases can also
identify complication of HCC, such as portal venous or hepatic invasion and vascular throm-
bosis [59]. Moreover, CT can be assessed to establish for other complications such as bleeding
and hemoperitoneum.
A vascular mass or a large necrotic mass strongly suggests HCC; however, other hepatic
lesions, benign or malignant, can mimic HCC on CT. On the other hand, false-negative CT
imaging also can occur. In case of a cirrhotic liver with elevated AFP, and if the diagnosis is
not absolute, MRI or other imaging modalities can assist in this differentiation.
2.2.3. Magnetic resonance imaging
MRI is the best test for evaluating HCC in patients with liver lesion detected by abnormal US.
HCC appearance varies on MRI depending on multiple factors, such as hemorrhage, degree
of fibrosis, histologic pattern, degree of necrosis, and the amount of fatty change.
HCC on T1-weighted images may be isointense, hypointense, or hyperintense relative to the
liver. On T2-weighted images, HCC is usually hyperintense. Precontrast and postcontrast MRI
has a 70–85% chance of detecting a solitary mass of HCC [60]. However, MRI sensitivity is the
lowest when evaluating tumors <2 cm in diameter [51].
MRI can help differentiate cirrhotic nodules from HCC: (1) If the mass is bright on T2-weighted
images, it is HCC until proven otherwise; (2) if the mass is dark on T1- and T2-weighted images,
it is a siderotic regenerative nodule or siderotic dysplastic nodule; (3) if the mass is bright on
T1-weighted images and dark or isointense on T2-weighted images, it is a dysplastic nodule
or low-grade HCC [61].
Hepatocyte-specific contrast-enhanced MRI including such as gadolinium-enhanced MRI
typically demonstrates an increasing number of subcentimetre cirrhotic nodules and that are
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often confirmed as HCCs or high-grade dysplastic nodules by these techniques [62]. The
diagnosis can be confirmed as HCC nodules if these subcentimetre hypervascular nodules
show arterial phase enhancement and “washout”, diffusion restriction or hyperintensity on
T2-weighted imaging and hypointensity on the hepatobiliary phase.
However, dysplastic nodules and, less likely, regenerative nodules can show similar enhance-
ment. The degree of enhancement varies, particularly with the degree of necrosis in larger
tumors. In addition, a “flash filling” haemangioma can have rapid arterial enhancement but
could be differentiated by lack of washout on delayed images. Besides, keep in mind that
gadolinium-based contrast agents have been linked to the development of nephrogenic
systemic fibrosis or nephrogenic fibrosing dermopathy [63].
Recent studies showed that contrast agents other than gadolinium-based contrast media might
demonstrate HCC. Super paramagnetic iron oxide (SPIO) particles used alone or in conjunction
with gadolinium-based contrast agents [64] have been shown to be highly sensitive for the
detection of HCC, particularly for small tumors. Double-contrast MR imaging (SPIO and
gadolinium) is highly sensitive (92%) in the diagnosis of hepatocellular carcinomas of 10 mm
or larger, but success in the definition of tumors smaller than 10 mm is still problematic [64,
65]. When uptake by Kupffer cells is reduced in the Kupffer phase of SPIO-enhanced MRI,
malignancy should be highly suspected [64, 66].
A recent study showed that dynamic gadobenate dimeglumine (which is hepatocyte
selective agent and shows extracellular distribution)-enhanced MRI has a sensitivity of 80–
85% and a positive predictive value of 65–66% in the detection of HCC. The technique,
however, is of limited value for detecting and characterizing lesions smaller than 1 cm in
diameter [67].
The only hepatocyte-selective contrast agent that has been approved for clinical use is
mangafodipir trisodium can evaluate questionable lesions in the liver. Mangafodipir trisodium
is taken up by normal hepatocytes and masses that contain hepatocytes, causing increased
signal intensity on T1-weighted images. This agent may help differentiate a tumor of hepato-
cellular origin, such as HCC, from secondary hepatic masses [68].
Although MRI is the most useful test to make a diagnosis, the nodules sometimes might not
distinguish. In case the nodules have not specific features of HCC and the diagnosis is still
unclear, advance imaging modalities or histological examination is needed.
2.2.4. Other imaging modalities
The less invasive imaging studies including dynamic CT, MRI, and CEUS have replaced
conventional angiography for the diagnosis of HCC [69]. The role of positron emission
tomography (PET) in the diagnostic and staging evaluation of HCC still remains uncertain.
Several studies have suggested a role for [18F] fluorodeoxyglucose (FDG)-PET scanning for
the detection of primary HCCs, tumor staging, assessing response to therapy, and for predict-
ing prognosis as an adjunct to CT [70, 71]. The sensitivity of PET in diagnosis of HCC was 55%
compared with 90% for CT scanning, although only PET detected some tumors (including
distant metastases). Well-differentiated and low-grade tumors had lower activity on PET and
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correspondingly lower PET scores [71, 72]. However, FDG-PET might be a useful imaging
modality for identifying extrahepatic metastases, although sensitivity is limited for lesions 1
cm or smaller [73].
2.3. Pathology
Pathological diagnosis of HCC is recommended for all nodules occurring in non-cirrhotic
livers, and for those patients with inconclusive or atypical imaging appearance in cirrhotic
livers. While taking a biopsy in lesions 1–2 cm and in lesions >2 cm with atypical vascularization
on dynamic imaging was recommended by EASL, ASLD, and Japan guideline, APASL and
KLCSG-NCC guidelines recommend either biopsy or follow-up could be used for indetermi-
nate nodules on imaging workup [2–7].
Sensitivity of liver biopsy depends upon location, size, and expertise and might range
between 70 and 90% for all tumor sizes. However, there is no recommendation on prioritizing
strategy for indeterminate nodules. The issue is also related to the need of risk stratification
of atypical nodules in cirrhosis using ancillary findings. Importantly, “threshold growth” is
included as a main diagnostic criterion in LI-RADS and the Organ Procurement and
Transplantation Network (OPTN) system introduced by the United Network for Organ
Sharing (UNOS). OPTN-UNOS guidelines allow the diagnosis of arterial-phase hyperen-
hancing HCCs using threshold growth, defined as growth >50% in ≤6 months [74].
Pathological diagnosis is particularly complex for small nodules because minute biopsy
specimens may not contain intratumoral portal tracts, thus precluding the detection of stromal
invasion. Therefore, core biopsy is commonly used to diagnosis for these small nodules. Core
liver biopsy is definitely superior to fine-needle aspiration, because the increased amount of
tissue obtained is appropriate for the valuation of both architectural and cytologic features.
Furthermore, the tissue block obtained obtains materials for marker studies. Fine-needle
aspiration is usually used for the evaluation of large lesions that are likely to be moderately to
poorly differentiate [75].
The histologic appearance of HCC can range from well differentiated (with individual
hepatocytes appearing nearly identical to normal hepatocytes) to poorly differentiated lesions
consisting of large multinucleate anaplastic tumor giant cells. Central necrosis of large tumors
is common. Bile globules and acidophilic (hyaline) inclusions are occasionally present.
In some cases, dysplasia rather than carcinoma is diagnosed. There is an ongoing debate about
the usefulness of various grades of dysplasia in predicting the ultimate development of HCC
in dysplastic nodules.
In case of, the diagnosis is not clearly HCC, and sample should be stained with CD34, CK7,
glypican 3, HSP-70, and glutamine synthetase to improve diagnostic accuracy [3]. Additional
staining can be considered to detect progenitor cell features (K19 and EpCAM) or assess
neovascularization (CD34) [2].
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3. Summary
Early diagnosis of HCC is too important because early diagnosis of HCC provides curative
treatment of HCC. The risk population for HCC should be determined and these patients
should be entered into a surveillance program. When a nodule/nodules detected, convenient
test should be used to identify the nodule. Recent guidelines are practical and recommend
noninvasive criteria in terms of implementing diagnostic criteria using four-phase CT or
contrast-enhanced MRI, and establishing criteria for subcentimetre-sized HCCs. Although
there are several remaining issues including diagnostic criteria of non-hypervascular hypoin-
tense nodules, almost all suspicious lesion of liver can be defined by serum markers, imaging
series, and contribution of biopsy because the characteristics of HCC are sufficiently clear.
Conflict of interest
No conflict of interest was declared by the authors.
Financial disclosure
The authors declared that this study has received no financial support.
Author details
Ayse Kefeli1*, Sebahat Basyigit2 and Abdullah Ozgur Yeniova1
*Address all correspondence to: aysekefeli@hotmail.com
1 Gastroenterology Department, Gaziosmanpasa University, Tokat, Turkey
2 Gastroenterology Department, Artvin State Hospital, Artvin, Turkey
References
[1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman CA. Global cancer statistics.
Cancer J Clin. 2011;61(2):69.
[2] European Association for the Study of the Liver, European Organisation for Research
and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of
hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
Updates in Liver Cancer108
[3] Bruix J, Sherman M. American Association for the Study of Liver Diseases. Manage-
ment of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
[4] Omata M, Lesmana L, Tateishi R, Chen P,Lin S et al. Asian Pacific Association for the
Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol
Int. 2010;4:439–474
[5] Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH consensus-based
clinical practice guidelines for the management of hepatocellular carcinoma: 2014
update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3:458–468.
[6] Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC)
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice
guideline for the management of hepatocellular carcinoma. Korean J Radiol.
2015;16:465–522.
[7] Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, et al. Increased survival
of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.
Gastroenterology. 2004;126(4):1005–1014.
[8] American College of Radiology. Liver imaging reporting and data system (LI-RADS).
American College of Radiology. [Accessed August 1, 2015]. Web site. http://
www.acr.org/Quality-Safety/Resources/LIRADS Published May 25, 2014.
[9] El-Bahrawy M. Alpha-fetoprotein-producing non-germ cell tumours of the female
genital tract. Eur J Cancer. 2010;46:1317.
[10] Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273.
[11] Wu JT. Serum alpha-fetoprotein and its lectin reactivity in liver diseases: a review. Ann
Clin Lab Sci. 1990;20:98.
[12] Chen DS, Sung JL, Sheu JC, Lai MY, How SW, et al. Serum alpha-fetoprotein in the early
stage of human hepatocellular carcinoma. Gastroenterology. 1984;86:1404.
[13] Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C et al. Hepatocel-
lular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675.
[14] Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting
hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical
analysis. Ann Intern Med. 2003;139:46.
[15] Lee E1, Edward S, Singal AG, Lavieri MS, Volk M. Improving screening for hepatocel-
lular carcinoma by incorporating data on levels of α-fetoprotein, over time. Clin
Gastroenterol Hepatol. 2013;11:437–440.
[16] Mehta A, Singal AG. Hepatocellular carcinoma surveillance: does alpha-fetoprotein
have a role? Gastroenterology. 2015;149(3):816–8817.
Diagnosis of Hepatocellular Carcinoma
http://dx.doi.org/10.5772/64992
109
[17] Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular
carcinoma: impact of the MELD allocation system and predictors of survival. Gastro-
enterology. 2008;134:1342.
[18] Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D et al. Report of a national
conference on liver allocation in patients with hepatocellular carcinoma in the United
States. Liver Transpl. 2010;16:262.
[19] Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms,
epitopes, and conformational variants. Exp Biol Med. 2001;226(5):377–408.
[20] Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, et al. Clinical utility of highly
sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carci-
noma patients with alpha-fetoprotein <20 ng/mL. Cancer Sci. 2011;102(5):1025–1031.
[21] Oda K, Ido A, Tamai T, Matsushita M, Kumagai K, et al. Highly sensitive lens culinaris
agglutinin-reactive α-fetoprotein is useful for early detection of hepatocellular carci-
noma in patients with chronic liver disease. Oncol Rep. 2011;26(5):1227–1233.
[22] Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. Characterization of microRNAs in serum: a novel
class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):
997–1006.
[23] Yu L, Gong X, Sun L, Zhou Q, Lu B, Zhu L. The circular RNA Cdr1as act as an oncogene
in hepatocellular carcinoma through targeting miR-7 expression. PLoS One.
2016;11(7):e0158347.
[24] Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, et al. Argonaute2 complexes
carry a population of circulating microRNAs independent of vesicles in human plasma.
Proc Natl Acad Sci USA. 2011;108:5003–5008.
[25] Boeri M, Verri C, Conte D, Roz L, Modena P, et al. MicroRNA signatures in tissues and
plasma predict development and prognosis of computed tomography detected lung
cancer. Proc Natl Acad Sci USA. 2011;108:3713–3718.
[26] Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets
for therapy. Int J Biochem Cell Biol. 2010;42:1273–1281.
[27] Wen Y, Han J, Chen J, Dong J, Xia Y, et al. Plasma miRNAs as early biomarkers for
detecting hepatocellular carcinoma. Int J Cancer. 2015;137(7):1679–1690. doi:10.1002/ijc.
29544.
[28] Khoury S, Tran N. Circulating microRNAs: potential biomarkers for common malig-
nancies. Biomarkers Med. 2015;9:131–151.
[29] Carr B, Kanke F, Wise M, Satomura S. Clinical evaluation of Lens culinaris agglutinin-
reactive alpha-fetoprotein and des-gamma-carboxyprothrombin in histologically
proven hepatocellular carcinoma in the United States. Dig Dis Sci. 2007;52:776–778.
Updates in Liver Cancer110
[30] Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, et al. South Tohoku District Study
Group. Am J Gastroenterol? 2000;95(4):1036–1040.
[31] Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM. Prognostic and diagnostic
value of des-gamma-carboxyprothrombin in liver cancer. Drug News Perspect.
2010;23(8):498–508.
[32] Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, et al. Des-gamma-carboxyprothrombin,
alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepato-
cellular carcinoma. J Gastroenterol Hepatol. 2008;23:1541–1548.
[33] Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, et al. Clinical significance of simultane-
ous determinations of alpha-fetoprotein and des-gamma-carboxyprothrombin in
monitoring recurrence in patients with hepatocellular carcinoma. Cancer. 1996;77(9):
1781.
[34] Yao M, Yao DF, Bian YZ, Zhang CG, Qiu LW, et al. Oncofetal antigen glypican-3 as a
promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary
Pancreat Dis Int. 2011;10:289–294.
[35] Li B, Liu H, Shang HW, Li P, Li N, Ding HG. Diagnostic value of glypican-3 in alpha
fetoprotein negative hepatocellular carcinoma patients. Afr Health Sci. 2013;13:703–
709.
[36] Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, et al. Identification of
soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage
hepatocellular carcinoma. Cancer Res. 2004;64(7):2418–2423.
[37] Hui Liu, Peng Li, Yun Zhai, Chun-FengQu, Li-Jie Zhang, et al. Diagnostic value of
glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastro-
enterol. 2010;16(35):4410–4415.
[38] Kimhofer T, Fye H, Taylor-Robinson S, Thursz M, and Holmes E. Proteomic and
metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J
Cancer. 2015;112(7):1141–1156.
[39] Kew MC, Wolf P, Whittaker D, Rowe P. Tumour-associated isoenzymes of gamma-
glutamyl transferase in the serum of patients with hepatocellular carcinoma. Br J
Cancer. 1984;50(4):451.
[40] Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, et al. Clinical evaluation of urinary
transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of
hepatocellular carcinoma. Br J Cancer. 1997;75(10):1460.
[41] Takahashi H, Saibara T, Iwamura S, Tomita A, Maeda T, et al. Serum alpha-L-fucosidase
activity and tumor size in hepatocellular carcinoma. Hepatology. 1994;19(6):1414.
Diagnosis of Hepatocellular Carcinoma
http://dx.doi.org/10.5772/64992
111
[42] Na K, Jeong SK, Lee MJ, Cho SY, Kim SA, et al. Human liver carboxylesterase 1
outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma
from other liver diseases in Korean patients. Int J Cancer. 2013;133(2):408–415.
[43] Lu Y, Li N, Gao L, Xu YJ, Huang C, et al. Acetylcarnitine is a candidate diagnostic and
prognostic biomarker of hepatocellular carcinoma. Canc Res. 2016;76(10):2912–2920.
[44] Reynolds AR, Furlan A, Fetzer DT, asatomi E, Borhani AA, et-al. Infiltrative hepato-
cellular carcinoma: what radiologists need to know. Radiographics. 2015;35(2):371–386.
[45] Lau WY. Hepatocellular Carcinoma. World Scientific Pub Pte Ltd Co Inc., Singapore
596224; 2008. ISBN: 9812707999. P. 193–199
[46] Malhi H, Grant EG, Duddalwar V. Contrast-enhanced ultrasound of the liver and
kidney. Radiol. Clin. North Am. 2014;52(6):1177–1190.
[47] Kim TK, Jang HJ, Wilson SR. Imaging diagnosis of hepato-cellular carcinoma with
differentiation from other pathology. Clin Liver Dis. 2005;9:253–279.
[48] Ma Y, Zhang XL, Li XY, Zhang L, Su HH, Zhan CY. Value of computed tomography
and magnetic resonance imaging in diagnosis and differential diagnosis of small
hepatocellular carcinoma. Nan Fang Yi Ke Da XueXueBao. 2008;28(12):2235–2238.
[49] Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the
prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhanc-
ing liver mass. Liver Transpl. 2005;11:281–289.
[50] Kim SH, Choi BI, Lee JY, Kim SJ, So YH, Eun HW. Diagnostic accuracy of multi-/single-
detector CT and contrast- enhanced MRI in the detection of hepatocellular carcinomas
meeting the Milan criteria before liver transplantation. Intervirology. 2008;51(Suppl 1):
52–60.
[51] Krinsky GA, Lee VS, Theise ND, Weinreb JC, Rofsky NM, et al. Hepatocellular
carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with
MR imaging and explantation correlation. Radiology. 2001;219:445–454.
[52] Ebara M, Ohto M, Watanabe Y, Kimura K, Saisho H, et al. Diagnosis of small hepato-
cellular carcinoma: correlation of MR imaging and tumor histologic studies. Radiology.
1986;159:371–377.
[53] Holland AE, Hecht EM, Hahn WY, Kim DC, Babb JS, et al. Importance of small (B20-
mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of
the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology.
2005;237:938–944.
[54] Baron RL, Peterson MS. From the RSNA refresher courses: screening the cirrhotic liver
for hepatocellular carcinoma with CT and MR imaging: opportunities and pitfalls.
Radiographics. 2001;21:117–132.
Updates in Liver Cancer112
[55] Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular
carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311–
330.
[56] Choi BI, Lee KH, Han JK, Lee JM. Hepatic arterioportal shunts: dynamic CT and MR
features. Korean J Radiol. 2002;3(1):1–15.
[57] Kim KW, Kim MJ, Lee SS, Kim HJ, Shin YM, et-al. Sparing of fatty infiltration around
focal hepatic lesions in patients with hepatic steatosis: sonographic appearance with
CT and MRI correlation. AJR Am J Roentgenol. 2008;190(4):1018–1027.
[58] Hong HS, Kim HS, Kim MJ, De Becker J, Mitchell DG, Kanematsu M. Single breath-
hold multiarterial dynamic MRI of the liver at 3T using a 3D fat-suppressed keyhole
technique. J Magn Reson Imaging. 2008;28(2):396–402.
[59] Takayasu K, Furukawa H, Wakao F, Muramatsu Y, Abe H et al. CT diagnosis of early
hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR Am
J Roentgenol. 1995;164(4):885–890.
[60] Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford).
2005;7(1):26–34.
[61] Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-
associated hepatocellular nodules: correlation of histopathologic and MR imaging
features. RadioGraphics. 2008;28(3):747–769.
[62] Golfieri R, Grazioli L, Orlando E, Dormi A, Lucidi V, et al. Which is the best MRI marker
of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase
alone or combined with other features? Classification after Gd-EOB-DTPA adminis-
tration. J Magn Reson Imaging. 2012;36:648–657.
[63] Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, et al. Nephrogenic systemic
fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic
resonance imaging. J Am SocNephrol. 2006;17(9):2359–2362.
[64] Bhartia B, Ward J, Guthrie JA, Robinson PJ. Hepatocellular carcinoma in cirrhotic livers:
double-contrast thin-section MR imaging with pathologic correlation of explanted
tissue. AJR Am J Roentgenol. 2003;180:577–584.
[65] Ward J, Guthrie JA, Scott DJ, Atchley J, Wilson D, et al. Hepatocellular carcinoma in the
cirrhotic liver: double- contrast MR imaging for diagnosis. Radiology. 2000;216:154–
162.
[66] Imai Y, Murakami T, Yoshida S, Nishikawa M, Ohsawa M, et al. Super paramagnetic
iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correla-
tion with histological grading. Hepatology. 2000;32:205–212.
Diagnosis of Hepatocellular Carcinoma
http://dx.doi.org/10.5772/64992
113
[67] Choi SH, Lee JM, Yu NC, Suh KS, Jang JJ, et al. Hepatocellular carcinoma in liver
transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
AJR Am J Roentgenol. 2008;191:529–536.
[68] Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology.
2001;218:27–38.
[69] Kanematsu M, Hoshi H, Imaeda T, Murakami T, Inaba Y, et al. Detection and charac-
terization of hepatic tumors: value of combined helical CT hepatic arteriography and
CT during arterial portography. AJR Am J Roentgenol. 1997;168:1193–1198.
[70] Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, et al. The role of (18)F-FDG-PET imaging
for the selection of liver transplantation candidates among hepatocellular carcinoma
patients. Liver Transpl. 2006;12:1655–1660.
[71] Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, et al. Positron emission
tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol.
2000;32:792–797.
[72] Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, et al. Fluorine-18 FDG positron
emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol.
1999;94:3314–3319.
[73] Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, et al. 18F-FDG PET in the
detection of extra- hepatic metastases from hepatocellular carcinoma. J Gastroenterol.
2004;39:961–968.
[74] Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS
policy for liver transplant allocation: standardization of liver imaging, diagnosis,
classification, and reporting of hepatocellular carcinoma. Radiology. 2013;266:376–382.
[75] International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of
early hepatocellular carcinoma: a report of the international consensus group for
hepatocellular neoplasia. Hepatol. 2009;49:658–664.
Updates in Liver Cancer114
